| The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation (NCT06504186) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-01 |
| Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia (NCT06608342) | Institute of Hematology & Blood Diseases Hospital, China | 2024-06-25 |
| Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL (NCT06481241) | Institute of Hematology & Blood Diseases Hospital, China | 2024-06-10 |
| Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL (NCT06481228) | Institute of Hematology & Blood Diseases Hospital, China | 2024-06-04 |
| A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP (NCT06658834) | Institute of Hematology & Blood Diseases Hospital, China | 2024-06-01 |
| R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (NCT06594640) | Institute of Hematology & Blood Diseases Hospital, China | 2024-05-30 |
| MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL (NCT06367374) | Institute of Hematology & Blood Diseases Hospital, China | 2024-05-30 |
| Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL (NCT06489808) | Institute of Hematology & Blood Diseases Hospital, China | 2024-05-28 |
| MRD-positive AML Clinical Study (NCT07131059) | Institute of Hematology & Blood Diseases Hospital, China | 2024-05-11 |
| A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma (NCT06464185) | Institute of Hematology & Blood Diseases Hospital, China | 2024-04-30 |
| Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) (NCT06287567) | Institute of Hematology & Blood Diseases Hospital, China | 2024-04-17 |
| VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT (NCT06447090) | Institute of Hematology & Blood Diseases Hospital, China | 2024-04-12 |
| Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL (NCT06387121) | Institute of Hematology & Blood Diseases Hospital, China | 2024-04-02 |
| Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia (NCT06281327) | Institute of Hematology & Blood Diseases Hospital, China | 2024-03-01 |
| Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution. (NCT06208137) | Institute of Hematology & Blood Diseases Hospital, China | 2024-02-29 |
| Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia (NCT06265545) | Institute of Hematology & Blood Diseases Hospital, China | 2024-02-22 |
| CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. (NCT06231368) | Institute of Hematology & Blood Diseases Hospital, China | 2024-02-04 |
| Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA (NCT06254287) | Institute of Hematology & Blood Diseases Hospital, China | 2024-02-01 |
| CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy (NCT06212154) | Institute of Hematology & Blood Diseases Hospital, China | 2024-01-20 |
| Safety and Efficacy Study of NGGT003 in Hemophilia A Patients (NCT06238908) | Institute of Hematology & Blood Diseases Hospital, China | 2024-01-17 |
| GVM±R in Patients With Relapsed or Refractory Aggressive NHL. (NCT06244368) | Institute of Hematology & Blood Diseases Hospital, China | 2024-01-17 |
| A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia (NCT06199089) | Institute of Hematology & Blood Diseases Hospital, China | 2024-01-16 |
| Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients (NCT06219239) | Institute of Hematology & Blood Diseases Hospital, China | 2024-01-04 |
| Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT06547944) | Institute of Hematology & Blood Diseases Hospital, China | 2024-01-01 |
| Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP) (NCT06168851) | Institute of Hematology & Blood Diseases Hospital, China | 2023-12-28 |
| Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (NCT06224257) | Institute of Hematology & Blood Diseases Hospital, China | 2023-12-03 |
| A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP) (NCT06094881) | Institute of Hematology & Blood Diseases Hospital, China | 2023-12-01 |
| DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma (NCT06158269) | Institute of Hematology & Blood Diseases Hospital, China | 2023-12-01 |
| Anti-CD38 Antibody Treating Evans Syndrome (NCT06014775) | Institute of Hematology & Blood Diseases Hospital, China | 2023-12-01 |
| An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute) (NCT06490549) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-30 |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma (NCT06415708) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-30 |
| Cohort of Nursing Homes (NCT07249086) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-30 |
| Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML (NCT06133556) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-24 |
| ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor (NCT05888870) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-22 |
| Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy (NCT06102694) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-16 |
| A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia (NCT06116318) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-01 |
| Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) (NCT06107582) | Institute of Hematology & Blood Diseases Hospital, China | 2023-11-01 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients (NCT06087419) | Institute of Hematology & Blood Diseases Hospital, China | 2023-10-30 |
| Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy (NCT06066242) | Institute of Hematology & Blood Diseases Hospital, China | 2023-10-01 |
| The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia (NCT06021977) | Institute of Hematology & Blood Diseases Hospital, China | 2023-09-01 |
| Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells (NCT06041620) | Institute of Hematology & Blood Diseases Hospital, China | 2023-08-31 |
| A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia (NCT05995054) | Institute of Hematology & Blood Diseases Hospital, China | 2023-08-28 |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia (NCT05979363) | Institute of Hematology & Blood Diseases Hospital, China | 2023-08-14 |
| Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia (NCT05941585) | Institute of Hematology & Blood Diseases Hospital, China | 2023-08-08 |
| Anti-CD38 Antibody Treating APS With Thrombocytopenia (NCT05983952) | Institute of Hematology & Blood Diseases Hospital, China | 2023-08-01 |
| Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD (NCT06698211) | Institute of Hematology & Blood Diseases Hospital, China | 2023-08-01 |
| Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia (NCT05987696) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-31 |
| Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia (NCT05975996) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-10 |
| Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT (NCT05923814) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-07 |
| Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT (NCT05914675) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-01 |
| Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT (NCT05914701) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-01 |
| Ruxolitinib as GVHD Prophylaxis in AA Patients (NCT05914714) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-01 |
| The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes (NCT05925504) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-01 |
| Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (NCT05870475) | Institute of Hematology & Blood Diseases Hospital, China | 2023-06-30 |
| YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT05913804) | Institute of Hematology & Blood Diseases Hospital, China | 2023-06-28 |
| A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation (NCT05904067) | Institute of Hematology & Blood Diseases Hospital, China | 2023-06-10 |
| Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy (NCT05991336) | Institute of Hematology & Blood Diseases Hospital, China | 2023-06-05 |
| BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT (NCT05846737) | Institute of Hematology & Blood Diseases Hospital, China | 2023-05-29 |
| A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (NCT05870917) | Institute of Hematology & Blood Diseases Hospital, China | 2023-05-23 |
| Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia. (NCT05860595) | Institute of Hematology & Blood Diseases Hospital, China | 2023-05-23 |
| An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (NCT05849740) | Institute of Hematology & Blood Diseases Hospital, China | 2023-05-22 |
| Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy (NCT06449482) | Institute of Hematology & Blood Diseases Hospital, China | 2023-05-05 |
| Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma (NCT06302699) | Institute of Hematology & Blood Diseases Hospital, China | 2023-05-01 |
| A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities (NCT05850286) | Institute of Hematology & Blood Diseases Hospital, China | 2023-04-21 |
| The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. (NCT05630651) | Institute of Hematology & Blood Diseases Hospital, China | 2023-04-19 |
| Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia (NCT05832216) | Institute of Hematology & Blood Diseases Hospital, China | 2023-04-17 |
| A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma (NCT05860036) | Institute of Hematology & Blood Diseases Hospital, China | 2023-04-04 |
| Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old (NCT05709288) | Institute of Hematology & Blood Diseases Hospital, China | 2023-03-23 |
| Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (NCT05958719) | Institute of Hematology & Blood Diseases Hospital, China | 2023-03-02 |
| TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) (NCT05718856) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-23 |
| Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness (NCT06254560) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-23 |
| LILRB4 STAR-T Cell Therapy for Monocytic Leukemia (NCT05739409) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-16 |
| Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (NCT05914662) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-15 |
| Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (NCT05676710) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-10 |
| Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia (NCT04390971) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-10 |
| Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model (NCT05599256) | Institute of Hematology & Blood Diseases Hospital, China | 2023-02-09 |
| A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia (NCT05694767) | Institute of Hematology & Blood Diseases Hospital, China | 2023-01-22 |
| Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model (NCT05600855) | Institute of Hematology & Blood Diseases Hospital, China | 2023-01-15 |
| PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy (NCT05676697) | Institute of Hematology & Blood Diseases Hospital, China | 2023-01-13 |
| Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (NCT05727917) | Institute of Hematology & Blood Diseases Hospital, China | 2023-01-01 |
| The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19) (NCT05659654) | Institute of Hematology & Blood Diseases Hospital, China | 2022-12-16 |
| CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT05654779) | Institute of Hematology & Blood Diseases Hospital, China | 2022-12-12 |
| A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia (NCT05562882) | Institute of Hematology & Blood Diseases Hospital, China | 2022-12-10 |
| Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (NCT05660785) | Institute of Hematology & Blood Diseases Hospital, China | 2022-12-01 |
| A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (NCT05583838) | Institute of Hematology & Blood Diseases Hospital, China | 2022-11-22 |
| Avatrombopag Combined With IST as First-line Treatment for SAA (NCT05720234) | Institute of Hematology & Blood Diseases Hospital, China | 2022-11-10 |
| Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma (NCT05846750) | Institute of Hematology & Blood Diseases Hospital, China | 2022-11-01 |
| Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study (NCT05846763) | Institute of Hematology & Blood Diseases Hospital, China | 2022-11-01 |
| A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive (NCT05603156) | Institute of Hematology & Blood Diseases Hospital, China | 2022-10-30 |
| Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy (NCT05456698) | Institute of Hematology & Blood Diseases Hospital, China | 2022-10-18 |
| Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease (NCT05601830) | Institute of Hematology & Blood Diseases Hospital, China | 2022-10-09 |
| Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL (NCT05594784) | Institute of Hematology & Blood Diseases Hospital, China | 2022-10-08 |
| The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients. (NCT05523128) | Institute of Hematology & Blood Diseases Hospital, China | 2022-09-29 |
| Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia (NCT05519384) | Institute of Hematology & Blood Diseases Hospital, China | 2022-09-14 |
| CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies (NCT05454241) | Institute of Hematology & Blood Diseases Hospital, China | 2022-09-07 |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL (NCT05495035) | Institute of Hematology & Blood Diseases Hospital, China | 2022-09-01 |
| Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma (NCT05549973) | Institute of Hematology & Blood Diseases Hospital, China | 2022-09-01 |
| Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease (NCT05531266) | Institute of Hematology & Blood Diseases Hospital, China | 2022-09-01 |
| ctDNA Methylation Sequencing for Myeloma (NCT05578625) | Institute of Hematology & Blood Diseases Hospital, China | 2022-08-31 |
| Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (NCT05660473) | Institute of Hematology & Blood Diseases Hospital, China | 2022-08-01 |